Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?

Gastroenterology. 2014 Mar;146(3):608-11. doi: 10.1053/j.gastro.2014.01.040. Epub 2014 Jan 24.

Authors

Neeraj Narula¹, Laurent Peyrin-Biroulet², Jean-Frederic Colombel³

Affiliations

¹ Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
² Inserm U954 and Department of Hepato-Gastroenterology, Université de Lorraine, Vandœuvre-lès-Nancy, France.
³ Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.

PMID: 24468168
DOI: 10.1053/j.gastro.2014.01.040

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Crohn Disease / drug therapy*
Female
Humans
Infliximab
Male
Methotrexate / therapeutic use*

Substances

Antibodies, Monoclonal
Infliximab
Methotrexate